{"nctId":"NCT00301366","briefTitle":"The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency","startDateStruct":{"date":"2006-06"},"conditions":["Alpha 1-Antitrypsin Deficiency"],"count":38,"armGroups":[{"label":"Alpha-1 Proteinase Inhibitor (Human), modified process","type":"EXPERIMENTAL","interventionNames":["Drug: alpha-1 proteinase inhibitor (human)"]}],"interventions":[{"name":"alpha-1 proteinase inhibitor (human)","otherNames":["Prolastin","Alpha-1 antitrypsin (AAT)","BAY x 5747","BAY 10-5233","TAL-05-00007"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of congenital Alpha1-antitrypsin deficiency\n* Documented forced expiratory volume in 1 second (FEV1 ) between 20% - 80% of predicted value within last 6 months.\n* Signed written informed consent prior to initiation of any study related procedures.\n\nExclusion Criteria:\n\n* Females who are pregnant, breast feeding, or if of child-bearing potential, unwilling to practice adequate contraception throughout the study\n* Use of systemic steroids within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids used on a routine or as needed basis).\n* Subjects who have had exacerbations of their disease within one month of trial entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion.","description":"An adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product. The adverse event does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["Nausea","Upper respiratory tract infection","Urinary tract infection","Chest pain","Influenza like illness"]}}}